PCSA (Processa Pharmaceuticals) ROC %: -563.86% (As of Mar. 2026)

What is Processa Pharmaceuticals ROC %?

Processa Pharmaceuticals PCSA +9.64% 28 ROC % is -563.86% as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Processa Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -563.86%.

As of today (2026-07-11), Processa Pharmaceuticals's WACC % is 20.38%. Processa Pharmaceuticals's ROC % is -918.34% (calculated using TTM income statement data). Processa Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Processa Pharmaceuticals (NAS:PCSA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Processa Pharmaceuticals's WACC % is 20.38%. Processa Pharmaceuticals's ROC % is -918.34% (calculated using TTM income statement data). Processa Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Processa Pharmaceuticals ROC % Related Terms

Processa Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals ROC % Chart

Processa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-120.92

-394.80

-1,405.77

-1,297.90

-784.58

Processa Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-902.02	-1,466.05	-1,360.23	-942.88	-563.86

28GF Score

Processa Pharmaceuticals Inc PCSA

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Processa Pharmaceuticals ROC % Calculation

Processa Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-13.989 * ( 1 - 0% )	/	( (1.423	+	2.143)	/ 2 )
=	-13.989	/	1.783
=	-784.58 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.229	-	1.46	-	( 1.191	-	max(0, 1.533	-	1.879	+	1.191	))
=	1.423

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.814	-	2.236	-	( 5.537	-	max(0, 2.236	-	5.671	+	5.537	))
=	2.143

Processa Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-13.324 * ( 1 - 0% )	/	( (2.143	+	2.583)	/ 2 )
=	-13.324	/	2.363
=	-563.86 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.814	-	2.236	-	( 5.537	-	max(0, 2.236	-	5.671	+	5.537	))
=	2.143

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.521	-	1.98	-	( 1.691	-	max(0, 1.98	-	1.938	+	1.691	))
=	2.583

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -563.86% mean?

Processa Pharmaceuticals (PCSA) has a ROC % of -563.86% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Processa Pharmaceuticals and its competitors.

Is Processa Pharmaceuticals' ROC % too high?

Processa Pharmaceuticals' current ROC % is -563.86%. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Processa Pharmaceuticals' ROC % compare to ELAB and MBIO?

Processa Pharmaceuticals' ROC % of -563.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current ROC % is -563.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Processa Pharmaceuticals stock overvalued right now?

Processa Pharmaceuticals (PCSA) has a current ROC % of -563.86%. The current ROC % is -563.86%. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current ROC % is -563.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ELAB MBIO DRMA LIMN TCRT GNPX MLEC CLGN CPMV ADIL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960

Website https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

28GF Score

Get the complete analysis for PCSA

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16

Price

View PCSA Analysis

See ROC % data for all stocks →